Pneumagen Ltd Announces Positive Anti–Viral Activity for Novel Glycan Approach in Preventing COVID–19 Infections
Pneumagen Ltd Leverages its Novel Glycan Approach to Target Coronavirus (COVID-19) Infections
Pneumagen Presents Poster on Multivalent Sialic Acid-binding Proteins as a Novel Preventative and Treatment of RSV at RSVVW 2019
Pneumagen Demonstrates Preclinical Proof-of-Concept in Oncology for Neumonco, a Novel Carbohydrate Binding Module
Pneumagen Demonstrates Preclinical Proof-of-Concept for Neumifil™ in Respiratory Syncytial Virus Infections
Pneumagen Appoints Scientific Advisory Board
Publication – Sialic Acid-Binding Protein Sp2CBMTD Protects Mice against Lethal Challenge with Emerging Influenza A (H7N9) Virus
PUBLICATION – Prevention of influenza by targeting host receptors using engineered proteins
Bio€quity Europe in San Sebastian, Spain | May 12th – 14th 2024
BioTrinity in London | April 23 – 24th 2024
J.P. Morgan Healthcare Conference and Biotech Showcase I January 8th – 11th 2024
Jefferies London Healthcare Conference I November 14th – 16th 2023
BARDA Industry Day in Washington I November 13th-14th 2023
BIO-Europe in Munich I November 6th-8th 2023
Bio€quity Europe in Dublin | May 14th – 16th 2023
BioTrinity in London | April 25 – 26th 2023
Biotech Showcase / JPM Week | January 9th – 11th 2023
